Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cel...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
Collaborators
NCT04161248 · Lymphoma, B-Cell
NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more
NCT06008691 · Non-Hodgkin Lymphoma, B-cell
NCT05940272 · Lymphoma, B-Cell, Lymphoma, and more
NCT06534437 · Non-Hodgkin Lymphoma, B-cell
Loyola University Medical Center, Foster G. McGraw Hospital and Satellites
Maywood, Illinois
Tufts Medical Center
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions